New HIV-prevention injection rolled out in Africa, studies show 99.9% risk reduction

South Africa, Eswatini, and Zambia begin administering lenacapavir, a new HIV-prevention injection. Lenacapavir, taken twice a year, reduces HIV transmission risk by over 99.9%. Gilead Sciences to provide lenacapavir at no profit to two million people in high HIV burden countries over three years.